Mucitus (erdosteine) capsules 150 mg. №12

Description

Mucitus composition
active substance: erdosteine;
1 capsule contains erdosteine ​​150 mg;
excipients: microcrystalline cellulose, povidone, sodium starch glycolate (type A), magnesium stearate;

Dosage form
Capsules.

Pharmacological properties
Erdosteine ​​is a mucolytic compound whose action is mediated by its active metabolites. These metabolites have free thiol groups, which break down the disulfide bridges that bind glycoprotein fibers and thus reduce the elasticity and viscosity of the mucus. As a result, the tool helps to clear the airways of secretions and increases the effectiveness of the mucociliary mechanism in the removal of mucus and mucopurulent secretions from the upper and lower respiratory tract.
Erdosteine ​​also reduces the adhesion of gram-positive and gram-negative bacteria to the airway epithelium. As a result of this antibacterial antiadhesive effect, which has been proven in in vitro studies, bacterial colonization of the airways may be reduced and the risk of bacterial superinfection reduced.

Indication
Reduction of viscosity and facilitation of expectoration of bronchial secretions in the treatment of acute and chronic diseases of the upper and lower respiratory tract, such as bronchitis, rhinitis, sinusitis, laryngopharyngitis, exacerbation of chronic bronchitis, chronic obstructive pulmonary disease (COPD), hyperchorachitis, hyperchondria.
Prevention of recurrent episodes of infections and complications after surgery, such as pneumonia or partial pulmonary atelectasis.
This drug is also indicated as concomitant antibiotic therapy in the case of bacterial respiratory infections.

Contraindication
Hypersensitivity to the active substance or to any of the excipients containing free SH groups.
You should stop using this drug in the following cases:

• in disorders of the liver (for example, with increased levels of alkaline phosphatase or transaminases in the serum);
• in renal failure (creatinine clearance <25 ml / min);
• in homocystinuria (this drug is a source of homocysteine, and currently no data are available on the use of erdosteine ​​in the case of congenital disorders of amino acid metabolism, especially in patients who are forced to follow a methionine-free diet);
• with peptic ulcer disease in the active phase.

Children
The drug is contraindicated in children under 8 years.

Use during pregnancy or breastfeeding
No cases of embryo / fetal malformations have been reported, but information on the use of erdosteine ​​during pregnancy or breastfeeding is limited. Therefore, the drug should be used during pregnancy, especially during the first trimester, only when absolutely necessary, after assessing the benefits / risks to the fetus and mother.

Method of application and dosage
Mucitus should be administered orally regardless of food intake.
For children aged 8 to 12 years, the recommended dose is 150 mg 2 times a day; adults and children over 12 years – 300 mg 2 times a day.
The course of treatment is determined by the doctor individually. In acute uncomplicated diseases, the drug should be used for 5-10 days. The duration of treatment for chronic diseases is determined by the doctor. Elderly patients do not require a change in dosage.

Overdose
No cases of overdose have been reported so far.
In case of overdose or accidental administration of this drug by a child, symptomatic therapy (gastric lavage and other supportive measures) is recommended.

Side effects
Occasionally, erdosteine ​​may cause gastrointestinal adverse reactions such as burning and stomach pain, nausea, vomiting, and, rarely, diarrhea. In several cases, ageusia or dysgeusia was observed at the beginning of therapy. Hypersensitivity reactions such as skin rash or unexpected hyperpyrexia, erythema, Quincke’s edema are rare. From the nervous system, a headache is possible.

Expiration date
2 years.

Storage conditions
Store Mucitus at a temperature not exceeding 30 ° C in the original package.
Keep out of reach of children.